protein

IFNGR1 Blocking Peptide

MBS8243331

1 mg

160 USD

Blocking Peptide

IFNGR1 Blocking Peptide

[IFNGR1]

[Interferon gamma receptor 1; IFN-gamma receptor 1; IFN-gamma-R1; CDw119; CD119]

[Interferon gamma receptor 1; Interferon gamma receptor 1; interferon gamma receptor 1; interferon gamma receptor 1; CDw119; CD_antigen: CD119]

[IFNGR1]

[IFNGR1; IFNGR1; CD119; IFNGR; IMD27A; IMD27B; IFN-gamma receptor 1; IFN-gamma-R1]

INGR1_HUMAN

Synthetic

Human, Mouse, Rat, Monkey

489

>85%

Lyophilized Powder

Shipping: Blue ice. Store at -20°C for one year.

Blocking (BL)

Blocking Peptide to the diluted primary antibody in a molar ratio of 10:1 (peptide to antibody) and incubate the mixture at 4 degree C for overnight or at room temperature for 2 hours.

Quality Control: The quality of the peptide was evaluated by reversed-phase HPLC and by mass spectrometry.

The peptide is used to block Anti-IFNGR1 Antibody reactivity.

124474

P15260.1

P15260

Chagas Disease (American Trypanosomiasis) Pathway (147809); Chagas Disease (American Trypanosomiasis) Pathway (147795); Cytokine Signaling In Immune System Pathway (1269310); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); HIF-1 Signaling Pathway (695200); Herpes Simplex Infection Pathway (377873); Herpes Simplex Infection Pathway (377865); IFN-gamma Pathway (138040); Immune System Pathway (1269170)

This gene (IFNGR1) encodes the ligand-binding chain (alpha) of the gamma interferon receptor. Human interferon-gamma receptor is a heterodimer of IFNGR1 and IFNGR2. A genetic variation in IFNGR1 is associated with susceptibility to Helicobacter pylori infection. In addition, defects in IFNGR1 are a cause of mendelian susceptibility to mycobacterial disease, also known as familial disseminated atypical mycobacterial infection. [provided by RefSeq, Jul 2008]

IFNGR1: Receptor for interferon gamma. Two receptors bind one interferon gamma dimer. Defects in IFNGR1 are a cause of mendelian susceptibility to mycobacterial disease (MSMD); also known as familial disseminated atypical mycobacterial infection. This rare condition confers predisposition to illness caused by moderately virulent mycobacterial species, such as Bacillus Calmette-Guerin (BCG) vaccine and environmental non-tuberculous mycobacteria, and by the more virulent Mycobacterium tuberculosis. Other microorganisms rarely cause severe clinical disease in individuals with susceptibility to mycobacterial infections, with the exception of Salmonella which infects less than 50% of these individuals. The pathogenic mechanism underlying MSMD is the impairment of interferon-gamma mediated immunity whose severity determines the clinical outcome. Some patients die of overwhelming mycobacterial disease with lepromatous-like lesions in early childhood, whereas others develop, later in life, disseminated but curable infections with tuberculoid granulomas. MSMD is a genetically heterogeneous disease with autosomal recessive, autosomal dominant or X-linked inheritance. Belongs to the type II cytokine receptor family. Protein type: Receptor, cytokine; Membrane protein, integral. Chromosomal Location of Human Ortholog: 6q23.3. Cellular Component: integral to plasma membrane; plasma membrane. Molecular Function: interferon-gamma receptor activity; interleukin-20 binding; protein binding. Biological Process: cytokine and chemokine mediated signaling pathway; response to virus; signal transduction. Disease: Helicobacter Pylori Infection, Susceptibility To; Hepatitis B Virus, Susceptibility To; Immunodeficiency 27a; Immunodeficiency 27b; Mycobacterium Tuberculosis, Susceptibility To

1 mg

160 USD

5 mg

305